Please ensure Javascript is enabled for purposes of website accessibility

Another Day, Another Big Pharma Breakup

By Dave Williamson – Feb 27, 2014 at 10:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Merck may be on the verge of making a very big move.

In this video from Thursday's Market Checkup, Motley Fool health -are analyst David Williamson discusses a number of pharmaceutical companies that have aggressively reshaped themselves recently to deal with the effects of a looming patent cliff. Now, it seems that Merck (MRK 0.22%) may be on the verge of making a similar move. It is rumored that the company's consumer unit may be up for sale, and with such brands as Dr. Scholl's, Claritin, and Coppertone under that umbrella, the news is understandably generating a lot of interest. The potential sale is expected to raise roughly $11 billion

In this segment, David discusses the details of the potential deal, as well as just how far that $11 billion would go in restocking Merck's pipeline. David then takes a look at that pipeline and discusses some of its underrated potential blockbuster candidates.

David Williamson owns shares of Merck, Novartis, and Procter & Gamble. The Motley Fool recommends Procter & Gamble. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Merck & Stock Quote
Merck &
MRK
$110.04 (0.22%) $0.24
Procter & Gamble Stock Quote
Procter & Gamble
PG
$150.61 (0.91%) $1.36
Bristol-Myers Squibb Stock Quote
Bristol-Myers Squibb
BMY
$81.13 (0.31%) $0.25
Novartis Stock Quote
Novartis
NVS
$89.99 (0.19%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.